Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

Antibody-drug conjugates (ADCs) have exhibited potent clinical benefits in cancer therapy. However, development of ADCs against epidermal growth factor receptor (EGFR) has limitations because of wide expression of EGFR in both normal and tumor tissues. Previously, we developed an anti-EGFR protease-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:MAbs
Main Authors: Yang, Yun, Guo, Qingcheng, Chen, Xi, Zhang, Junjie, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Li, Bohua, Guo, Yajun, Wang, Hao
פורמט: Artigo
שפה:Inglês
יצא לאור: Taylor & Francis 2016
נושאים:
Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966596/
https://ncbi.nlm.nih.gov/pubmed/26760045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1127491
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים